Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Revenue (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Revenue for 8 consecutive years, with $13000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 97.74% to $13000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $698000.0, a 99.07% decrease, with the full-year FY2024 number at $68.7 million, up 40.98% from a year prior.
  • Revenue was $13000.0 for Q3 2025 at Precision Biosciences, down from $18000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $68.8 million in Q2 2021 to a low of $13000.0 in Q3 2025.
  • A 5-year average of $13.6 million and a median of $7.4 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 6282.65% in 2021, then crashed 99.96% in 2025.
  • Precision Biosciences' Revenue stood at $6.3 million in 2021, then skyrocketed by 67.19% to $10.6 million in 2022, then tumbled by 33.59% to $7.0 million in 2023, then tumbled by 90.93% to $638000.0 in 2024, then crashed by 97.96% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Revenue are $13000.0 (Q3 2025), $18000.0 (Q2 2025), and $29000.0 (Q1 2025).